<DOC>
	<DOCNO>NCT00936741</DOCNO>
	<brief_summary>Participants study C-1073-400 ( NCT00569582 ) invite participate extension study examine long term safety mifepristone treatment sign symptoms endogenous Cushing 's syndrome . Total treatment duration may 12 month long discretion Investigator .</brief_summary>
	<brief_title>An Extension Study CORLUX Treatment Endogenous Cushing 's Syndrome</brief_title>
	<detailed_description>Up 50 subject receive mifepristone daily . Subjects complete 24 week mifepristone treatment Corcept protocol C1073-400 ( NCT00569582 ) eligible continue treatment additional 1 year . Assessments safety , evaluate physical examination , vital sign , laboratory test adverse event , make . Persistence improvement response mifepristone treatment also evaluate extension study assess continue sustained improvement sign symptoms Cushing 's syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Have complete Week 24 visit 6Week Followup visit Corcept Study C1073400 ( NCT00569582 ) . In opinion Investigator , expect maintain clinical benefit mifepristone . Women childbearing potential negative serum pregnancy test Entry . Women childbearing potential must willing use nonhormonal , medically acceptable method contraception study . Are able provide write informed consent Are able return investigative site complete study evaluation outline protocol . Will use systemic estrogen study . Have acute unstable medical problem , could aggravate mifepristone treatment . Are take medication within 14 day Entry visit ) large first pas metabolism largely mediate CYP3A4 narrow therapeutic margin ; and/or b ) strong CYP3A4 inhibitor . Female patient reproductive potential , pregnant unable unwilling use medically acceptable , nonhormonal method contraception study . Have receive investigational treatment ( drug , biological agent device ) CORLUX ( mifepristone ) within 30 day Entry Have history allergic reaction intolerance CORLUX ( mifepristone ) Have uncorrected hypokalemia ( potassium level &lt; 3.5 mEq/L ) Entry . Spironolactone eplerenone allow control hypokalemia . Postmenopausal woman history endometrial hyperplasia atypia pathological feature consistent endometrial carcinoma . Thickened endometrium Entry Visit transvaginal ultrasound resolve induction menstrual bleeding progesterone . Uncontrolled , clinically significant hypothyroidism hyperthyroidism . Any woman intact uterus hemorrhagic disorder treat anticoagulant ( e.g . warfarin , heparin ) . Have renal failure define serum creatinine ≥2.2 mg/dL . Elevated total bilirubin &gt; 1.5 ULN , elevate ALT AST ≥3X upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Cushing 's Disease</keyword>
	<keyword>Cushing 's Syndrome</keyword>
	<keyword>Cushings</keyword>
	<keyword>Pituitary</keyword>
	<keyword>ACTH</keyword>
	<keyword>Adrenocorticotropic hormone</keyword>
	<keyword>Ectopic</keyword>
	<keyword>Adrenal adenoma</keyword>
	<keyword>Adrenal carcinoma</keyword>
	<keyword>Adrenal autonomy</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Hypercortisolemia</keyword>
	<keyword>Cushingoid</keyword>
	<keyword>Moon facies</keyword>
	<keyword>Dorsocervical fat</keyword>
	<keyword>Plethora</keyword>
	<keyword>Hirsutism</keyword>
	<keyword>Violaceous stria</keyword>
	<keyword>Hormone</keyword>
	<keyword>Contraceptive</keyword>
	<keyword>Endocrine</keyword>
	<keyword>Cushing Syndrome</keyword>
	<keyword>Ectopic ACTH Secretion</keyword>
</DOC>